

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Novel Therapeutic Approaches to Tuberculosis (C7)

March 30-April 4, 2014 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Christopher M. Sassetti and Thomas G. Evans

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Global Health Travel Award Deadline: October 29, 2013 / Abstract & Scholarship Deadline: December 3, 2013 / Abstract Deadline: January 7, 2014 / Discounted Registration Deadline: January 29, 2014

SUNDAY, MARCH 30

MONDAY, MARCH 31

Keynote Address

Charles N. Serhan, Brigham and Women's Hospital, USA
Regulation of Acute Inflammation and Resolution : Lessons from Lipid Mediators

Inflammation: Balance between Bacterial Control and Immunopathology

David M. Tobin, Duke University Medical Center, USA
Eicosanoid Balances Determine TB Disease Progression

Andrea M. Cooper, Trudeau Institute, USA
Regulation of Pathology

Helen A. Fletcher, University of Oxford, UK
Role of Myeloid Signatures in the Prediction of Active Tuberculosis

Short Talk(s) Chosen from Abstracts

Strategies to Ameliorate Lung Damage

Paul T. Elkington, University of Southampton, UK
Targeting Matrix Metalloproteinase Activity to Reduce Immunopathology

Samuel M. Behar, Brigham and Women's Hospital, USA
Tissue-Protective Activities of Adaptive Immunity

Speaker to be Announced

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, APRIL 1

Novel Antimicrobial Strategies

Lalita Ramakrishnan, University of Washington, USA
Overcoming Environmentally-Induced Drug Tolerance

Terry Roemer, Merck, USA
Exploiting Chemical and Genetic Synergies to Improve Antibiotic Activity

William R. Bishai[†], Johns Hopkins School of Medicine, USA
KRITH Immunomodulation during Therapy

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

Host-Directed Antimicrobial Therapies

Kanury V. S. Rao, International Centre for Genetic Engineering and Biotechnology, India

Manipulating Host-Pathogen Crosstalk to Treat TB Infection

Daniel Kalman, Emory University, USA
Repurposing Host-Directed Drugs to Treat Infectious Disease

Robert J. Wilkinson, University of Cape Town, South Africa
The Interaction between Antimicrobial and Adjunctive Therapies and the Immune Response to Tuberculosis

Short Talk(s) Chosen from Abstracts

Poster Session 2

WEDNESDAY, APRIL 2

Targeting Persistent Bacterial Populations

Tawanda Gumbo, UT Southwestern Medical Center, USA
Accelerating the Kill of Tuberculosis Persisters: The Interaction of Drug Concentration and Novel Bacterial Complex Adaptive Systems

Stewart T. Cole, École Polytechnique Fédérale de Lausanne, Switzerland
Eradicating Persistent Bacteria

Christopher M. Sassetti, University of Massachusetts Medical School, USA
Bacterial Adaptations to the Host Environment

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

Therapy for Latent TB Infection

Gavin J. Churchyard, Aurum Institute, South Africa
Community/Population-Based Interventions for LTBI

Peter Andersen, Statens Serum Institut, Denmark
Development of an LTBI Vaccine

David M. Margolis, University of North Carolina at Chapel Hill, USA
Eradication of Latent Pathogens: Lessons from HIV

Short Talk(s) Chosen from Abstracts

Poster Session 3

THURSDAY, APRIL 3

Immunotherapy for Active Disease

Alan Sher, NIAID, National Institutes of Health, USA
Understanding and Modulating TB Disease

Anne O'Garra, MRC National Institute for Medical Research, UK
Biology and Therapeutic Potential of IL-10 Modulation

Gilla Kaplan[†], Public Health Research Institute, UMDNJ, USA
Changing the Course of TB Pathogenesis and Treatment

Steven Holland, NIAID, NIH, USA
Genetic Determinants of Reactivation

Short Talk(s) Chosen from Abstracts

Therapeutic Vaccines

Douglas Lowrie[†], Fudan University, China
Development of a Vaccine for the Treatment of MDR TB

Geneviève Inchauspe, Transgène, France
Immune Modulation in Latent and Active Disease through Vaccination

Rhea N. Coler, Infectious Disease Research Institute, USA
Preclinical and Clinical Testing of a Therapeutic Vaccine

Short Talk Chosen from Abstracts

FRIDAY, APRIL 4